|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Post-Traumatic Stress Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Disease | |||||
| Sleep Initiation and Maintenance Disorders | |||||
| Stress | |||||
| Stress Disorders, Post-Traumatic | |||||
| Stress Disorders, Traumatic | |||||
| 3 | More general conditions related to this trial | ||||
| Anxiety Disorders | |||||
| Dyssomnias | |||||
| Mental Disorders | |||||
| Nervous System Diseases | |||||
| Pathologic Processes | |||||
| Sleep Disorders | |||||
| Sleep Disorders, Intrinsic | |||||
| 4 | Interventions listed in this trial | ||||
| Prazosin | |||||
| Placebo | |||||
| Psychotherapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic alpha-Antagonists | |||||
| Adrenergic Antagonists | |||||
| Antihypertensive Agents | |||||
| Cardiovascular Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||